Dr. Reddy's Laboratories

RDY

Market cap $10.8B

Dr. Reddy's Laboratories NYSE: RDY said a scale-up issue tied to the active pharmaceutical ingredient for its semaglutide injection will temporarily delay commercial supplies, though management emphasized that products already supplied to the market are not affected and do not raise patient safety concerns.

Dr. Reddy's Laboratories Limited (RDY) Discusses Manufacturing Issue and Process Review for Semaglutide Transcript

Torrent Pharmaceuticals ​said ‌on Thursday it ​was ​voluntarily recalling ⁠select ​batches ​of its Semalix semaglutide ​injection ​disposable pens ‌after ⁠a product recall notification ​from ​its ⁠manufacturer ​Dr. ​Reddy's ⁠Laboratories.

Dr Reddy's Laboratories said on Thursday that it is delaying commercial ​supplies of semaglutide due to an issue ‌related to the active pharmaceutical ingredient used in the drug, sending its shares down.

HYDERABAD, India--(BUSINESS WIRE)---- $RDY #AmericanDepositaryReceipts--Dr. Reddy's Laboratories Limited announces filing of Annual Report on Form 20-F.

HYDERABAD, India & PRINCETON, N.J.--(BUSINESS WIRE)---- $RDY #Bosulif--Dr. Reddy's Laboratories Ltd. announced the first-to-market launch of Bosutinib Tablets 400mg, a generic equivalent of Bosulif® in the United States.

NYSE issues a pre-market daily advisory direct from the trading floor. NEW YORK, May 29, 2026 /PRNewswire/ -- The New York Stock Exchange (NYSE) provides a daily pre-market update directly from the NYSE Trading Floor.

HYDERABAD, India & MISSISSAUGA, Ontario--(BUSINESS WIRE)---- $RDY #DrReddy--Dr. Reddy's Laboratories Ltd. a global pharmaceutical company, today announced the launch of its generic Semaglutide Injection in Canada.

Dr. Reddy's Laboratories NYSE: RDY reported what Chief Financial Officer M.V. Narasimham described as a resilient FY 2026 performance, with record annual revenue despite pressure from lower lenalidomide sales and several one-time charges during the fourth quarter.

RDY stock down 5% on missing fiscal fourth-quarter 2026 earnings and revenue estimates as North America generics sales slumped.